Andy Hill Cancer Research Endowment
Public Hearing and Board Meeting Minutes

The following board members, constituting a quorum, were present:
Leslie Alexandre, Fred Appelbaum, Thomas Brown, David Byrd, Weihang Chai, Carol Dahl, Steve Harr, Eunice Hostetter, Jennifer Kampsula Wong

Board Members Absent: Elaine Albert, S. Lori Brown, Jim Hendricks

CARE Staff Attendees: Peter Choi, Laura Flores Cantrell

Guest Attendees: Julia Terlinchamp (WA Dept of Commerce); Thomas Bates (Insight Strategic Partners); Sarah Lyman (Empire Health Foundation); Jan Glick (Jan Glick & Associates); Laura Hitchcock (Jan Glick & Associates)

Cambia Grove, 1800 Ninth Ave., Suite 250, Seattle, WA | Friday, March 1, 2019 10:00 a.m.–1:00 p.m.

1. **Welcome** (Fred Appelbaum)
   A quorum being present, the meeting was called to order at 10:06 a.m.

2. **Public Hearing** (Fred Appelbaum)
   Fred Appelbaum opened the annual Public Hearing. With no members of the public present to participate or provide comment, the public hearing was adjourned.

3. **Consent Agenda** (Fred Appelbaum)
   Fred Appelbaum presented the consent agenda, which included:
   - December 12, 2018 Board Meeting Minutes
   - Board Expense Reimbursement Policy
   - Resolution regarding Officer Signing Authority

   **MOTION:** A motion to approve the consent agenda was made by Tom Brown, seconded by Leslie Alexandre, and unanimously approved.

4. **Draft Plan - Summary and Discussion of high-level feedback** (Jan Glick)
   Jan Glick outlined the purpose and plan for the strategic planning day and provided background on the development of the current Draft Strategic Plan.
   Board members provided feedback on the Draft Strategic Plan.

5. **CARE’s Unique Value Proposition as “Washington’s Cancer Research Endowment”** (Jan Glick)
   Jan Glick introduced a working draft “Unique Value Proposition” statement as a starting point for board discussion and to set the context for small group discussions.

   There was discussion on the desire to further develop the value proposition statement before moving to small group discussions. There was discussion on the unique value that CARE might provide to the state while advancing its mission.
6. Greater Focus For Greater Impact Discussion (Jan Glick)

Jan Glick presented the topic, “How might CARE uniquely build capacity for cancer research in Washington.”

There was discussion about CARE capital development needs to advance cancer research in the state. There was additional discussion regarding the risks and rewards of pursuing capital funding. Tom Brown and Steve Harr volunteered to serve as a resource for staff to explore cancer research needs related to capital and whether there is a unique role for CARE to advance cancer research by funding capital expenditures.

MOTION: A motion to create an ad hoc committee composed of Steve Harr and Tom Brown to explore potential capital needs in cancer research was made by Tom Brown, seconded by David Byrd, and unanimously approved.

Jan Glick presented the topic, “How might CARE uniquely improve health outcomes for underserved Washingtonians.”

There was discussion about RFPs to fund cancer risk reduction (i.e., obesity, tobacco, and vaping) and vaccine-preventable cancers research. There was discussion about the broad reach of these types of RFPs might have by population and geographically. The board requested additional information from local and regional experts on different funding models (e.g., seed funding, bridge funding, etc.) and the performance outcomes of other cancer grantmakers. The board requested a guest speaker be invited, perhaps from the Rivkin Center, to describe their funding model and how it demonstrates success.

MOTION: A motion was made for CARE staff to continue work on exploring cancer risk reduction and vaccine preventable cancer research RFPs by Tom Brown, seconded by Leslie Alexandre, and unanimously approved.

7. Building in Flexibility and Rightsizing Awards (Laura Flores Cantrell)

Laura Flores Cantrell provided background on CARE appropriations from the State. There was discussion on modifying CARE’s current award programs, in duration and amount of award. There was general agreement that it would be helpful to have additional information regarding other cancer funding models to help inform how Breakthrough Awards might be restructured or, potentially, replaced with a new model. There was discussion regarding maintaining a meaningful level of award amount for the Distinguished Researcher Awards in order to demonstrate impact.

The meeting was adjourned at 1:00 p.m.

Approved this date: 9/3/2019

Eunice Hostetter, CARE Board Secretary